Literature DB >> 23116575

Epidemiology and management of uveal melanoma.

Yoshihiro Yonekawa1, Ivana K Kim.   

Abstract

Uveal melanoma is the most common primary intraocular malignancy in adults. The disease overwhelmingly affects white populations. Other risk factors include fair skin, light iris color, ancestry from northern latitudes, and ocular/oculodermal melanocytosis. Historically, enucleation was the definitive treatment of uveal melanoma, but brachytherapy and proton beam irradiation are now the most commonly used treatment methods. However, there are still no effective therapies against metastatic uveal melanoma, which is almost always fatal. Continued advances in understanding of the molecular mechanisms of uveal melanoma will facilitate the identification of prognostic markers and therapeutic targets.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23116575     DOI: 10.1016/j.hoc.2012.08.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  25 in total

Review 1.  Latest developments in the biology and management of uveal melanoma.

Authors:  Sapna P Patel
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 2.  Nanomedicine in the application of uveal melanoma.

Authors:  Shuo You; Jing Luo; Hans E Grossniklaus; Ma-Ling Gou; Ke Meng; Qing Zhang
Journal:  Int J Ophthalmol       Date:  2016-08-18       Impact factor: 1.779

Review 3.  Tumor Characteristics, Genetics, Management, and the Risk of Metastasis in Uveal Melanoma.

Authors:  Erin E Nichols; Ann Richmond; Anthony B Daniels
Journal:  Semin Ophthalmol       Date:  2016-04-29       Impact factor: 1.975

4.  Targeting nucleotide exchange to inhibit constitutively active G protein α subunits in cancer cells.

Authors:  Michael D Onken; Carol M Makepeace; Kevin M Kaltenbronn; Stanley M Kanai; Tyson D Todd; Shiqi Wang; Thomas J Broekelmann; Prabakar Kumar Rao; John A Cooper; Kendall J Blumer
Journal:  Sci Signal       Date:  2018-09-04       Impact factor: 8.192

5.  Removal of the eye in a tertiary care center of China: a retrospective study on 573 cases in 20 years.

Authors:  Ying Zhang; Mao-Nian Zhang; Xin Wang; Xiao-Fei Chen
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

Review 6.  MicroRNA dysregulation in uveal melanoma: a new player enters the game.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen; Yang Jiang
Journal:  Oncotarget       Date:  2015-03-10

7.  Molecular characterization of melanoma cases in Denmark suspected of genetic predisposition.

Authors:  Karin A W Wadt; Lauren G Aoude; Lotte Krogh; Lone Sunde; Anders Bojesen; Karen Grønskov; Nine Wartacz; Jakob Ek; Morten Tolstrup-Andersen; Mette Klarskov-Andersen; Åke Borg; Steffen Heegaard; Jens F Kiilgaard; Thomas V O Hansen; Kerenaftali Klein; Göran Jönsson; Krzysztof T Drzewiecki; Morten Dunø; Nicholas K Hayward; Anne-Marie Gerdes
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

8.  Uveal melanoma cells utilize a novel route for transendothelial migration.

Authors:  Michael D Onken; Jinmei Li; John A Cooper
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

9.  Genetic markers of pigmentation are novel risk loci for uveal melanoma.

Authors:  Robert Ferguson; Matjaz Vogelsang; Esma Ucisik-Akkaya; Karan Rai; Robert Pilarski; Carlos N Martinez; Justin Rendleman; Esther Kazlow; Khagay Nagdimov; Iman Osman; Robert J Klein; Frederick H Davidorf; Colleen M Cebulla; Mohamed H Abdel-Rahman; Tomas Kirchhoff
Journal:  Sci Rep       Date:  2016-08-08       Impact factor: 4.379

10.  Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma.

Authors:  Wei Dai; Jingfeng Zhou; Bei Jin; Jingxuan Pan
Journal:  Sci Rep       Date:  2016-03-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.